Evaluation of the effects of N-acetylcysteine in patients with Helicobacter pylori infection

Evaluation of the effects of a four-drug regimen with N-acetylcysteine and comparing it with a four-drug regimen in eradicating Helicobacter pylori in patients with Helicobacter pylori infection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230629058615N3

Enrollment

153

Registered

2024-08-19

Start date

2025-02-19

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: The intervention group will be given amoxicillin (Farabi) (capsules, 1000 mg) twice a day (with breakfast and dinner), clarithromycin (Tehran Chemie) (capsules, 500 mg) twice a day (wi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Have not used antibiotics in the previous 3 months Have not used N-acetylcysteine in the previous 3 months

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding History of allergic reaction to any of the treatment components History of cancer stomach Severe liver failure Child-Pugh score B, C Severe renal failure GFR<30 ml/min History of gastrectomy

Design outcomes

Primary

Measure	Time frame
Eradocation rate of Helicobacter pylori. Timepoint: 28 days after finishing the intervention. Method of measurement: Stool exam antigen.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Rezazadeh

Iran University of Medical Sciences

rezazadeh.am@iums.ac.ir+98 912 729 8761

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026